Bayer leads new €20m consortium aiming to optimize drug design
This article was originally published in Scrip
Executive Summary
Bayer HealthCare and Leiden University of the Netherlands are set to co-ordinate a newly founded international consortium comprising 20 partners, with the aim of optimizing drug design to reduce the rate of failure in clinical trials. The consortium is backed by Europe's Innovative Medicines Initiative (IMI), which has given €20 million in funding.